MAYINGLONG PHARMACEUTICAL GROUP CO., LTD.

Highlights Mayinglong Pharmaceutical Group Co., LTD.

Equities

600993

CNE000001HN2

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
27.81 ^CNY	+0.40%		-1.73%	+15.01%

19/04	Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/04	Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	12/04	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/23/28	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	07/23/07	CI
Hangzhou Yunbai Pharmaceutical Technology Co., Ltd. agreed to acquire 86.816% of stake in Shenzhen Daphne Pharmaceautical Co.,Ltd from from Mayinglong Pharmaceutical Group Co., LTD., Huayi Development Co., Ltd., China Bao An Co., Ltd and Guofa Jianfu Industrial Co., Ltd. for approximately CNY 260 million.	14/22/14	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Half Year Ended June 30, 2022	19/22/19	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Full Year Ended December 31, 2021	22/22/22	CI
Mayinglong Pharmaceutical Group Co., LTD. Reports Earnings Results for the Nine Months Ended September 30, 2021	22/21/22	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	20/21/20	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	23/21/23	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	25/21/25	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	23/20/23	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	21/20/21	CI
Mayinglong Pharmaceutical Group Co., Ltd. Announces Cash Dividend for the Year 2019, Payable on July 30, 2020	22/20/22	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	24/20/24	CI
Mayinglong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	24/20/24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mayinglong Pharmaceutical Group Co., LTD.

Equities

600993

CNE000001HN2

Highlights

Filters